Core Insights - Zentalis Pharmaceuticals has appointed James B. Bucher as Chief Legal Officer and Corporate Secretary, effective September 18, 2025, following the departure of Andrea Paul [1][3] - Bucher brings over 30 years of legal experience in the life sciences sector, with expertise in corporate strategy, governance, capital raising, and mergers and acquisitions [2][3] - The company is focused on advancing its clinical development of azenosertib, a WEE1 inhibitor for ovarian cancer, and aims to build shareholder value [3][4] Company Overview - Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer [4] - Azenosertib is being evaluated in clinical trials as both a monotherapy and in combination across multiple tumor types, demonstrating anti-tumor activity and good tolerability [4] - The company is leveraging its capabilities to explore additional research opportunities for azenosertib beyond ovarian cancer [4]

Core Viewpoint - Phillips Edison & Company, Inc. (PECO) is set to present at the BofA Securities 2025 Global Real Estate Conference on September 10, 2025, highlighting its position as a leading owner and operator of grocery-anchored neighborhood shopping centers [1][2]. Company Overview - PECO is one of the largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers in the United States, founded in 1991 [3]. - The company has a vertically-integrated operating platform and a national footprint, managing 327 shopping centers, including 303 wholly-owned centers totaling 34.0 million square feet across 31 states [3]. - PECO's grocery anchors include major retailers such as Kroger, Publix, Albertsons, and Ahold Delhaize, providing necessity-based goods and services [3]. Event Details - The presentation at the BofA Securities 2025 Global Real Estate Conference will feature Chairman and CEO Jeff Edison, President Bob Myers, and CFO John Caulfield [2]. - The event is scheduled for September 10, 2025, at 3:00 p.m. Eastern Time, with a live webcast available [2].

Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [2] - The company's key products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX™ Platform, and StratX Lung Analysis Reports, which are designed for patients with severe emphysema/COPD [2] - The Zephyr Valve has received FDA pre-market approval as a "breakthrough device" and is commercially available in over 25 countries, recognized as a standard treatment option for improving patient outcomes [2] Upcoming Investor Conferences - Pulmonx management will present at the Wells Fargo Healthcare Conference on September 4 at 1:30 pm PT/4:30 pm ET in Boston, MA, featuring a fireside chat and 1x1 meetings [1] - The company will also participate in the Lake Street Best Ideas Growth (BIG9) Conference on September 11 in New York, NY, focusing on 1x1 meetings [1] - A live and archived webcast of the fireside chat will be accessible on the "Investors" section of the Pulmonx website [1]

Core Viewpoint - Calavo Growers, Inc. is set to release its financial results for the fiscal third quarter ended July 31, 2025, on September 9, 2025, after market close [1]. Company Overview - Calavo Growers, Inc. is a global leader in the processing and distribution of avocados, tomatoes, papayas, and guacamole [2]. - The company operates under the Calavo brand name, along with proprietary sub-brands, private labels, and store brands [2]. - Founded in 1924, Calavo has a strong culture of innovation, sustainable practices, and market growth [2]. - The company serves various sectors including retail grocery, foodservice, club stores, mass merchandisers, food distributors, and wholesalers worldwide [2]. - Calavo is headquartered in Santa Paula, California, with facilities across the U.S. and Mexico [2].

Core Insights - nCino, Inc. reported strong financial results for Q2 FY2026, exceeding guidance for total and subscription revenues, as well as non-GAAP operating income, indicating robust customer demand and confidence in its AI-banking strategy [2][6][7] Financial Highlights - Total revenues for Q2 FY2026 were $148.8 million, a 12% increase from $132.4 million in Q2 FY2025 - Subscription revenues reached $130.8 million, up 15% from $113.9 million year-over-year - Non-GAAP operating income increased by 56% to $30.0 million compared to $19.3 million in the same quarter last year - GAAP net loss attributable to nCino was $(15.3) million, compared to $(11.0) million in Q2 FY2025, while non-GAAP net income was $25.7 million, up 64% from $15.6 million [6][7][11] Recent Business Highlights - nCino expanded relationships with two top-50 U.S. banks and a top-5 Canadian bank, enhancing its market presence - The company signed its first customer in Spain, a non-bank lender, to leverage nCino's solutions for scaling its lending business - nCino renewed and expanded its relationship with a British challenger bank, incorporating Client Lifecycle Management for efficient onboarding and compliance monitoring - A top-25 home builder's lending division signed on for nCino Mortgage to support nationwide growth [6][7][9] Financial Outlook - For Q3 FY2026, nCino expects total revenues between $146.0 million and $148.0 million, with subscription revenues between $127.5 million and $129.5 million - The company anticipates non-GAAP operating income between $31.5 million and $33.5 million, and non-GAAP net income per diluted share of $0.20 to $0.21 - For the full fiscal year 2026, total revenues are projected between $585.0 million and $589.0 million, with subscription revenues between $513.5 million and $517.5 million [5][11]

CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the closing of its previously announced private placement. The private placement was made to top-tier institutional and accredited investors, for total up front gross proceeds of approximately $25 million, before deducting fees and expenses. Immuneering sold: (i) an aggregate of 6,329,113 unregistered shares of the company’s C ...

EMERYVILLE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces its Board of Directors and the Special Transaction Committee of the Board of Directors has declared a one-time special cash dividend of $0.80 per share of common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. “This special dividend reflects our commitment to creatin ...

Group 1 - Insight Molecular Diagnostics Inc. (iMDx) announced participation in investor conferences hosted by H.C. Wainwright and Lake Street Capital Markets [1] - The H.C. Wainwright 27th Annual Global Investment Conference will take place on September 8-9, 2025, featuring a company presentation on September 8 at 5:00 pm ET [1] - The Lake Street Capital Markets 9th Annual Best Ideas Growth Conference (BIG9) is scheduled for September 11, 2025, with a format of one-on-one meetings [1] Group 2 - Insight Molecular Diagnostics is focused on democratizing access to novel molecular diagnostic testing to improve patient outcomes [2] - The company holds several trademarks, including GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ [2]

REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. Seer’s management is scheduled to participate in a fireside chat on Tuesday, September 9th at 12:20 p.m. Eastern Time / 9:20 a.m. Pacific Time. A live webcast of the session will be available on the Investor sectio ...

Group 1 - Lesaka Technologies, Inc. plans to release its fourth quarter and year-end 2025 results after the U.S. market close on September 10, 2025 [1] - A presentation webcast and conference call will be hosted by Lesaka management on September 11, 2025, at 8:00am EDT, followed by a live Q&A session for analysts and investors [1] - An archived version of the webcast will be available on Lesaka's Investor Relations website after the presentation [4] Group 2 - Lesaka operates as a South African fintech company, providing financial services, software, and business services to underserved consumers and merchants in Southern Africa [4] - The company offers an integrated multiproduct platform that includes transactional accounts, lending, insurance, merchant acquiring, cash management, software, and Alternative Digital Payments (ADP) [4] - Lesaka has a primary listing on NASDAQ and a secondary listing on the Johannesburg Stock Exchange [5]